ACET - NASDAQ

Adicet Bio, Inc.

Adicet Bio, Inc.

ACETยทNASDAQ

$8.15

+4.1%
HealthcareBiotechnology

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$76.18M
EPS-16.9500
P/E Ratio-0.48
Earnings Date08/06/2026
Adicet Bio, Inc.

Adicet Bio, Inc. Fair Value Envelope

ACET ยท NASDAQ

Our analysis suggests that ACET has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $8.1488, this represents a potential HIDDEN relative to our calculated worth for Adicet Bio, Inc..

HIDDEN
Intrinsic Value
Current Price: $8.1488

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$536.1M
+ Cash & Equivalents$38.9M
Firm Value-$497.1M
- Debt$14.7M
Equity Value-$511.9M
/ Shares Outstanding91,682,318B
DCF Value-$6
OVERVALUED BY 169%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$91.7M
-$88.3M
-$85.0M
-$81.8M
-$78.8M
-$75.8M
-$73.0M
-$70.3M
-$67.6M
-$65.1M
Maintenance CapEx
-$334.6K
-$322.1K
-$310.1K
-$298.6K
-$287.4K
-$276.7K
-$266.4K
-$256.4K
-$246.9K
-$237.7K
Owner Earnings
-$92.0M
-$88.6M
-$85.3M
-$82.1M
-$79.0M
-$76.1M
-$73.3M
-$70.5M
-$67.9M
-$65.4M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$85.2M
-$76.0M
-$67.7M
-$60.4M
-$53.8M
-$48.0M
-$42.7M
-$38.1M
-$34.0M
-$30.3M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your ACET research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.